Enzymatica AB (FRA:EN9) Total Equity: €10.30 Mil (As of Mar. 2026)


FRA:EN9 Enzymatica AB FRA:EN9
36 GF Score
Price €0.20
GF Value €0.17
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Enzymatica AB Total Equity?

Enzymatica AB FRA:EN9 +3.17% 36 Total Equity is €10.30 Mil as of Mar. 2026. GuruFocus rates FRA:EN9 with a GF Score™ of 36/100 and a GF Value™ of €0.17 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Enzymatica AB's total equity for the quarter that ended in Mar. 2026 was €10.30 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Enzymatica AB Total Equity Historical Data

* Premium members only.

The historical data trend for Enzymatica AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzymatica AB Total Equity Chart

Enzymatica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.17 11.49 6.85 15.33 11.41

Enzymatica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.42 13.05 12.33 11.41 10.30
FRA:EN9
36GF Score
Enzymatica AB FRA:EN9
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enzymatica AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Enzymatica AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=13.047-1.636
=11.41

Enzymatica AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=11.89-1.595
=10.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €10.30 Mil mean?
Enzymatica AB (FRA:EN9) has a Total Equity of €10.30 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Enzymatica AB and its competitors.
Is Enzymatica AB's Total Equity too high?
Enzymatica AB's current Total Equity is €10.30 Mil. Overall, Enzymatica AB has a GF Score™ of 36/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Total Equity compare to ZTS and UTHR?
Enzymatica AB's Total Equity of €10.30 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Enzymatica AB and its competitors. Enzymatica AB's current Total Equity is €10.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €0.20 — trading 14.7% above its estimated fair value. The current Total Equity is €10.30 Mil. Enzymatica AB's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current Total Equity is €10.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (FRA:EN9) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued. The current stock price of €0.20 is trading 14.7% above its estimated GF Value™ of €0.17. GuruFocus considers Enzymatica AB to be Modestly Overvalued.

Key valuation signals for FRA:EN9:

  • Total Equity: €10.30 Mil
  • GF Value™: €0.17 vs. price of €0.20 (14.7% above fair value)
  • GF Score™: 36/100 with 2 warning signs

No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enzymatica AB Business Description

Other Exchanges ENZY:Sweden
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
36GF Score

Get the complete analysis for FRA:EN9

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.17
GF Value